175 related articles for article (PubMed ID: 33551122)
1. [Pharmacoresistance to psychotropic drugs in children and adolescents: Pharmacogenetic anomalies of cytochrome P450 2D6].
David A; Fernandez A; Menard ML; Dor E; Leali G; Maria F; Cruzel C; Askenazy F; Verstuyft C; Thümmler S
Encephale; 2021 Jun; 47(3):227-234. PubMed ID: 33551122
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
3. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6.
Thümmler S; Dor E; David R; Leali G; Battista M; David A; Askenazy F; Verstuyft C
Front Psychiatry; 2018; 9():2. PubMed ID: 29472872
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
Quaranta S; Dupouey J; Colle R; Verstuyft C
Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
[TBL] [Abstract][Full Text] [Related]
7. Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors.
Gressier F; Verstuyft C; Hardy P; Becquemont L; Corruble E
J Neural Transm (Vienna); 2015 Jan; 122(1):35-42. PubMed ID: 25047911
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting.
Tonti E; Lee YM; Gruenke N; Ferren J; Stutzman DL
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):52-60. PubMed ID: 38377527
[No Abstract] [Full Text] [Related]
10. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
Kirchheiner J; Rodriguez-Antona C
CNS Drugs; 2009; 23(3):181-91. PubMed ID: 19320528
[TBL] [Abstract][Full Text] [Related]
11. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
Müller DJ; Kekin I; Kao AC; Brandl EJ
Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
[TBL] [Abstract][Full Text] [Related]
12. [Farmacogenetica in de psychiatrie; de huidige status quo].
van Westrhenen R; Birkenhäger TK
Tijdschr Psychiatr; 2022; 64(5):312-316. PubMed ID: 35735043
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
[TBL] [Abstract][Full Text] [Related]
14. Contrasting
Kalla P; Namerow LB; Walker SA; Ruaño G; Malik S
Pharmacogenomics; 2023 Feb; 24(3):131-139. PubMed ID: 36727491
[TBL] [Abstract][Full Text] [Related]
15. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
16. The use of pharmacogenetic testing in psychiatry.
Kumar A; Kearney A
J Am Assoc Nurse Pract; 2021 Nov; 33(11):849-851. PubMed ID: 34747904
[TBL] [Abstract][Full Text] [Related]
17. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
18. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Caudle KE; Sangkuhl K; Whirl-Carrillo M; Swen JJ; Haidar CE; Klein TE; Gammal RS; Relling MV; Scott SA; Hertz DL; Guchelaar HJ; Gaedigk A
Clin Transl Sci; 2020 Jan; 13(1):116-124. PubMed ID: 31647186
[TBL] [Abstract][Full Text] [Related]
19. A Review of the Important Role of
Taylor C; Crosby I; Yip V; Maguire P; Pirmohamed M; Turner RM
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33143137
[TBL] [Abstract][Full Text] [Related]
20. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
